Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events — SCALE-HF 1  

Heart Failure Clinical Trial

Official title: Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events - SCALE-HF 1

Status Active, not recruiting

Clinical Trial Summary

The main goal of this study is to use data from the Bodyport scale to help detect of worsening heart failure (HF) early.

Clinical Trial Description

The overarching goal of this prospective, multicenter study is to utilize data from the Bodyport scale to develop an index that allows for the early detection of worsening heart failure (HF). The Bodyport scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.

The SCALE-HF program will consist of multiple phases. For SCALE-HF 1, patients will be prospectively enrolled and utilize the Bodyport scale on a daily basis. Patients and clinicians will be blinded to the results other than data readily available from other devices such as body weight. There will be no attempt to influence clinical practice. Patients will be followed remotely for suspected clinical events. ;

Related Conditions & MeSH terms

• Heart Failure

• NCT number: NCT04882449
• Study type: Interventional
• Source: Bodyport Inc.
• Status: Active, not recruiting
• Phase: N/A
• Start date: July 8, 2021
• Completion date: December 31, 2022